Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GCK | P35557 | 13/20 | 0.47 |
| ▸ | GCKR | Q14397 | 13/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177953 | 0.80 | TDP1 (0.67) | TDP1HTR2AKCNH2CYP2C9LMNA | |
| SCHEMBL11480360 | 0.79 | KDM4E (0.58) | KDM4EGCKGCKRHTR2AKCNH2 | |
| SCHEMBL17337 | 0.77 | KDM4E (0.56) | KDM4EGCKGCKRCYP2C9LMNA | |
| SCHEMBL1104635 | 0.76 | — | — | |
| SCHEMBL18503 | 0.73 | GCK (0.60) | KDM4EGCKGCKR | |
| SCHEMBL11498349 | 0.71 | KDM4E (0.53) | KDM4EGCKGCKRLMNANAMPT | |
| SCHEMBL15689622 | 0.71 | KDM4E (0.53) | KDM4EGCKGCKRHTR2AKCNH2 | |
| SCHEMBL15232660 | 0.71 | KDM4E (0.53) | KDM4EGCKGCKRHTR2AKCNH2 | |
| SCHEMBL20754355 | 0.71 | ALDH1A1 (0.67) | KDM4ETDP1CYP3A4 | |
| SCHEMBL18651835 | 0.71 | TDP1 (0.55) | TDP1HTR2AKCNH2CYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858852-B1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2009-07-01 | — | — | EP | disclosed |
| US-20080280956-A1 | Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists | GILLIGAN MYRA | 2008-11-13 | — | — | US | disclosed |
| EP-1858852-A1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006095205-A1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280956-A1 | Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists | HTR2A, HTR2B, HTR2C | KDM4E 3074/4885GCK 2952/4885GCKR 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.